Abstract Purpose of Review In the preceding decade, the management of metastatic
cutaneous melanoma has been revolutionised with the development of highly effective …

Simple Summary The introduction of immune checkpoint inhibitors and targeted therapy for
the treatment of unresectable advanced or metastatic melanoma has changed the prognosis …

Introduction: Melanoma therapies have evolved rapidly, and initial successes have
translated into survival gains for patients with advanced melanoma. Both targeted and …

In recent years, several drugs have been approved for the treatment of patients with
metastatic cutaneous melanoma, completely reshaping the landscape of this aggressive …

The introduction in clinical practice of new drug compounds both targeted therapies anti-
BRAF and checkpoint inhibitors have largely improved our potential to manage advanced …

Metastatic melanoma is an aggressive form of cancer characterised by poor prognosis and a
complex etiology. Until 2010, the treatment options for metastatic melanoma were very …

Melanoma is increasing in incidence and remains a major public health threat. Although the
disease may be curable when identified early, advanced melanoma is characterized by …

Nowadays, oncogene‐directed therapy and immunotherapy represent the two most
promising avenues for patients with metastatic melanoma. The recent oncogene‐directed …

For patients with metastatic melanoma, there are currently several effective therapeutic
options. The BRAF inhibitors vemurafenib and dabrafenib are characterized by rapid tumor …

Cutaneous melanoma remains the most lethal of the primary cutaneous neoplasms, and
although the incidence of primary melanoma continues to rise, the mortality from metastatic …